AmberGen

AmberGen

Biotechnology Research

Billerica, MA 1,037 followers

Transforming Diagnostics & Drug Discovery

About us

AmberGen® is a biotechnology company and producer of Miralys™ spatial biology imaging solutions. Miralys™, also known as MALDI HiPLEX-IHC, is a new breakthrough method for targeted intact protein imaging that has unique multimodal imaging capabilities. First introduced in 2022, it has gained significant traction, including 8 of the top 10 pharma companies, as well as many of the world’s premier research institutions. It is currently being used to study tissues for a wide range of diseases including cancers, Alzheimer’s and Parkinson’s diseases; and even COVID. Benefits include: - Drug/target co-localization on the same sample, same instrument - The ability to produce images that co-register small molecule lipids and metabolites as well as the intact targeted proteins. - The product’s combination of fast, targeted, protein imaging (scan time as short as 45 min and 1cm2), ultra-high plex (10 to 100+), wide viewing area (up to 25 x 75 mm), and multi-modal capability make it an ideal technology for doing initial scans to identify regions of interest for later deep-dive analysis. - Miralys™ requires no dedicated instrument, and minimal investment to start using. It is used on MALDI Mass Spec Imaging instruments that your institution most likely already owns, such as the industry-leading instruments from our partner, Bruker Corporation.

Industry
Biotechnology Research
Company size
11-50 employees
Headquarters
Billerica, MA
Type
Privately Held
Founded
1993
Specialties
mass spectrometry, MALDI, MALDI Imaging, MSI, and Spatial Biology

Locations

Employees at AmberGen

Updates

Similar pages

Browse jobs

Funding

AmberGen 3 total rounds

Last Round

Grant

US$ 200.0K

Investors

MassVentures
See more info on crunchbase